The latest price target for Kezar Life Sciences (NASDAQ:KZR) was reported by Wells Fargo on November 14, 2024. The analyst firm set a price target for $11.00 expecting KZR to rise to within 12 months (a possible 44.36% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Kezar Life Sciences (NASDAQ:KZR) was provided by Wells Fargo, and Kezar Life Sciences maintained their equal-weight rating.

There is no last upgrade for Kezar Life Sciences

The last downgrade for Kezar Life Sciences Inc happened on October 2, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Kezar Life Sciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a maintained with a price target of $20.00 to $11.00. The current price Kezar Life Sciences (KZR) is trading at is $7.62, which is out of the analyst’s predicted range.